Document is current
Any future updates will be listed below
-
Authors
Parashar, Deepak https://orcid.org/0000-0002-5062-8950
Geethadevi, Anjali https://orcid.org/0000-0001-5486-7919
McAllister, Donna
Ebben, Johnathan
Peterson, Francis C.
Jensen, Davin R.
Bishop, Erin
Pradeep, Sunila
Volkman, Brian F. https://orcid.org/0000-0002-6681-5179
Dwinell, Michael B.
Chaluvally-Raghavan, Pradeep https://orcid.org/0000-0002-8268-3460
James, Michael A. https://orcid.org/0000-0002-8112-1108
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA229907)
- License Information
-
More Information
Article History
Received: 24 October 2019
Accepted: 6 January 2021
First Online: 2 March 2021
Competing interests
: Dr. James is an inventor on pending and awarded patents related to anti-CLPTM1L agents used in these studies and the founder of Essential Biotechnology LLC. The remaining authors declare no competing interests.
